Clinical trials: Oesophageal Cancer Metastatic
Gastric Cancer, Gastroesophageal-junction Cancer
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
This is a Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal…
- Conditions
- Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer, Pancreatic Cancer
- Trial name
- NCT05539430
- Testing
- LB1908
- Where
- 9 sites in United States
- Volunteers
- 56 people
- Sponsor
- Legend Biotech USA Inc
Esophageal Neoplasms
PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer
The treatment efficacy for stage IVb esophageal cancer has been improved through chemotherapy combined with immunotherapy recently.
- Trial name
- NCT06086457
- Testing
- Radiation, TP or PF regimen depended on investigator's choice., PD-1 inhibitor
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Gastric Neoplasms, Esophageal Cancer
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
This research study aims to evaluate the safety and determine the optimal dose of a new experimental drug, vvDD-hIL2 (vaccinia virus double-deleted human interleukin 2), in patients with advanced abdominal cancer.
- Conditions
- Gastric Neoplasms, Esophageal Cancer, Liver Cancer, Liver Metastasis
- Trial name
- RIOT3 (NCT07001592)
- Testing
- vvDD-hIL-2-RG-1
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Cancer, Esophagus Squamous Cell Carcinoma
Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy
This is prospective research study which will include patients with recurrent or metastatic squamous cell carcinoma of the head and neck, esophagus and anal canal starting on first-line platinum based chemotherapy or any line of…
- Conditions
- Cancer, Esophagus Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Anal Canal Squamous Cell Carcinoma
- Trial name
- MASST (NCT03712566)
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- University Health Network, Toronto
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Esophageal Neoplasms
Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer
Histological Node Negative thoracic esophageal squamous cell carcinoma（pN0 ESCC） after radical resection still carries the risk of recurrence after complete surgical resection, especially in some high-risk patients.
- Trial name
- NCT02891083
- Testing
- Adjuvant chemotherapy (Paclitaxel and Cisplatin), Adjuvant radiotherapy, Control group (Surgery alone)
- Where
- China
- Volunteers
- 486 people
- Sponsor
- Shanghai Chest Hospital
Metastatic Sarcoma, Esophageal Cancer
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to…
- Conditions
- Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- PHANTOM (NCT06298916)
- Testing
- 64Cu-LNTH-1363S
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Lantheus Medical Imaging
Esophageal Squamous Cell Carcinoma
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
This trial is a registrational Phase II/III, randomized, controlled, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with tislelizumab ± 5-FU in patients with unresectable, locally…
- Trial name
- NCT07554456
- Testing
- BL-B01D1, Tislelizumab, 5-Fluorouracil
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Stomach and Gastro-Esophageal Junction (GEJ) Cancer
Nab-Paclitaxel as Salvage Treatment in Locally Advanced or Metastatic Gastric Cancer
The investigators propose to study the efficacy and safety of nab-Paclitaxel in a Phase II trial of patients with locally advanced or metastatic adenocarcinomas of the stomach and gastro-esophageal junction
- Trial name
- NCT02251951
- Testing
- nab-Paclitaxel
- Where
- 6 sites in Greece
- Volunteers
- 39 people
- Sponsor
- Hellenic Oncology Research Group
Esophageal Cancer
Anlotinib Combined With PD-1 Inhibitors for Advanced/Metastatic Esophageal Cancer
Efficacy and Safety of Anlotinib combined with PD-1 inhibitors as 2 or more lines treatment for Heavily Pretreated Patients With Advanced, Metastatic Squamous Cell Carcinoma of the Esophagus.
- Trial name
- APEC (NCT04984096)
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
Solid Tumors
Study of INCB123667 in Subjects With Advanced Solid Tumors
This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with…
- Trial name
- NCT05238922
- Testing
- INCB0123667, Palbociclib, Bevacizumab
- Where
- 41 sites in United States, France and 6 more
- Volunteers
- 291 people
- Sponsor
- Incyte Corporation
Hepatic Arterial Infusion Chemotherapy, Liver Metastases
HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma
Patients with liver metastasis from esophagus squamous (ESC) are usually offered systemic therapy. However, for those with predominant liver disease or failure of system therapy, local liver management becomes an option.
- Conditions
- Hepatic Arterial Infusion Chemotherapy, Liver Metastases, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06184841
- Testing
- HAIC combined with intravenous PD-1
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peking University Cancer Hospital & Institute
Esophageal Cancer, Gastric Cancer
Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.
- Trial name
- NCT00032123
- Testing
- erlotinib hydrochloride
- Where
- 107 sites in United States, Canada
- Sponsor
- SWOG Cancer Research Network
Esophageal Cancer
Effect of Cervical Paraesophageal Lymph Node Metastasis Versus Supraclavicular Lymph Node Metastasis on the Overall Survival of Patients With Thoracic Esophageal Squamous Cell Carcinoma: An Observational Study
The goal of this observational study is to learn about in health conditions of ESCC. The main question[s] it aims to answer are: •Lymph node metastasis(LNM) in cervical paraesophageal or supraclavicular which influence OS more.
- Trial name
- ECPLNMvsSLNM (NCT06165094)
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Stomach Neoplasms, Esophageal Neoplasms
Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors
This study is for patients who have stomach cancer or cancer of the lower part of the esophagus that has spread to other organs. There are many different chemotherapy treatments for this type of cancer.
- Trial name
- NCT00515216
- Testing
- 5-fluorouracil, Oxaliplatin, Leucovorin
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Vanderbilt University
Esophageal Cancer, Gastric Cancer
Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005607
- Testing
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride
- Where
- 4 sites in United States
- Sponsor
- Robert H. Lurie Cancer Center
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Advanced Upper Gastrointestinal Tract Adenocarcinoma
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) monoclonal antibody domvanalimab, the anti programmed cell…
- Trial name
- STAR-221 (NCT05568095)
- Testing
- Domvanalimab, Zimberelimab, Capecitabine
- Where
- 168 sites in United States, Argentina and 27 more
- Volunteers
- 1,040 people
- Sponsor
- Arcus Biosciences, Inc.
Stomach Neoplasms, Esophageal Neoplasms
A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
The purpose of this study is to determine the maximum tolerated dose (MTD) of BMS-833923 administered in combination with Cisplatin and Capecitabine as first-line therapy in subjects with inoperable metastatic gastric…
- Trial name
- NCT00909402
- Testing
- BMS-833923, Cisplatin, Capecitabine
- Where
- 6 sites in United States, Canada and 2 more
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Refractory or Metastatic Esophageal Squamous Cell Carcinoma
A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma
The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus radiotherapy and S-1 for treatment of refractory or metastatic esophageal squamous cell carcinoma.
- Trial name
- NCT03320629
- Testing
- apatinib S-1 radiotherapy, S-1 radiotherapy
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Hebei Medical University Fourth Hospital